Other reports demonstrated CD25 expression in lymphocytic leukemias and some lymphomas, and it was therefore reasoned that the IL-2 receptor could be a target for immunotherapy in hematological neoplasms (29). This evidence concerns the gene IL2RA and hematopoietic and lymphoid system neoplasm.